Condensed Consolidated Statements of Cash Flows (USD $) In Thousands, unless otherwise specified	9 Months Ended
	Sep. 29, 2013	Sep. 30, 2012
Operating activities:
Net income	$ 100,339	$ 85,796
Add: net income from discontinued operations and dispositions, net of income taxes	(815)	(1,163)
Net income from continuing operations	99,524	84,633
Adjustments to reconcile net income from continuing operations to net cash provided by continuing operations:
Restructuring and lease charges, net	23,713	21,034
Depreciation and amortization	96,453	94,791
Stock-based compensation	11,423	15,352
Amortization of deferred debt issuance costs	2,598	2,655
Gains on disposition	(1,566)	0
Amortization of acquired inventory revaluation	203	4,774
Changes in operating assets and liabilities which provided (used) cash, excluding effects from companies purchased and divested:
Accounts receivable, net	26,839	15,088
Inventories, net	(31,782)	(24,447)
Accounts payable	(6,035)	(18,611)
Accrued expenses and other	(134,391)	(79,725)
Excess tax benefit from exercise of equity grants	0	(1,767)
Net cash provided by operating activities of continuing operations	86,979	113,777
Net cash (used in) provided by operating activities of discontinued operations	(91)	(1,131)
Net cash provided by operating activities	86,888	112,646
Investing activities:
Capital expenditures	(31,564)	(24,350)
Proceeds from Life Insurance Policies	783	0
Proceeds from dispositions of property, plant and equipment, net	52,202	0
Changes in restricted cash balances	0	(670)
Payments for acquisitions and investments, net of cash and cash equivalents acquired	(7,049)	(6,750)
Net cash used in investing activities of continuing operations	14,372	(30,430)
Net cash provided by investing activities of discontinued operations	494	1,976
Net cash used in investing activities	14,866	(28,454)
Financing activities:
Payments on debt	(429,000)	(333,000)
Proceeds from borrowings	419,000	291,000
Payments of debt issuance costs	0	(416)
Payments for (Proceeds from) Hedge, Financing Activities	1,363	0
Payments on other credit facilities	5,530	(143)
Payments for acquisition-related contingent consideration	0	(12,459)
Excess tax benefit from exercise of equity grants	0	1,767
Proceeds from stock options exercised	15,292	22,944
Purchases of common stock	(127,186)	(2,092)
Dividends paid	(23,733)	(23,875)
Net cash (used in) provided by financing activities	(138,734)	(56,274)
Effect of exchange rate changes on cash and cash equivalents	(2,161)	568
Net (decrease) increase in cash and cash equivalents	(39,141)	28,486
Cash and cash equivalents at beginning of period	171,444	142,342
Cash and cash equivalents at end of period	$ 132,303	$ 170,828